Navigation Links
Heska Announces Sixth Consecutive Profitable Quarter
Date:2/17/2012

LOVELAND, Colo., Feb. 17, 2012 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and other specialty veterinary products, today reported financial results for its fourth quarter and full year ended December 31, 2011.

Fourth Quarter 2011 Highlights:

  • Core Companion Animal Health revenue increased approximately 6.4%, while Other Vaccines, Pharmaceuticals and Products revenue decreased approximately 9.1% as compared to the fourth quarter of 2010.  In the third quarter of 2010, the USDA validated an improved process for a line of cattle vaccines, allowing Heska to ship a significant quantity of product in a category which had previously been on hold due to regulatory concerns.
  • Consolidated revenue increased 3.3% to $15.5 million, from $15.0 million in the fourth quarter of 2010.
  • 7.3% increase in year-over-year quarterly gross profit and a 42.5% gross margin, which is a 1.6 percentage point improvement compared to 40.9% in the fourth quarter of 2010.
  • $414 thousand in operating income compared to $688 thousand in operating income in the fourth quarter of 2010.  The Company has invested in expanding and improving its sales organization, as well as in developing new products to be introduced during 2012.
  • Heska completed the year with $6.3 million in cash, no debt and $19.6 million in working capital.
  • Full Year 2011 Highlights:

  • Full year revenue increased approximately 7% to $70.1 million compared to revenue of $65.5 million in the prior year.
  • Core Companion Animal Health revenue grew 3.3% to $57.5 million and Other Vaccines, Pharmaceuticals and Products revenue increased 28.5% to $12.6 million as compared to the prior year.
  • Gross profit was $29.2 million, or 41.7% gross margin, compared with gross profit of $24.8 million, or 37.9% gross margin in 2010.
  • Operating income was $3.2 million compared to operating income of $358 thousand in 2010.
  • "Heska achieved another quarter of profitability, improving gross profit and gross margin expansion," commented Robert Grieve, Heska's Chairman and CEO.  "We ended 2011 with solid momentum, even as we invest in our sales organization and in exciting new product opportunities, in advance of expected growth in 2012.  These investments are key to our growth objectives, and I am encouraged with the progress we have made.  We added new personnel to fill vacant sales territories and most positions are now filled.  We've been encouraged with our success in identifying and hiring talented people, the impact of our training and the speed at which these new hires have come to know their assigned territories.  We expect to hit full stride with our direct selling efforts by mid-year. This enhancement of our sales capabilities should begin to drive revenue growth in the upcoming quarters."

    "Our focus on new products is also progressing nicely," added Dr. Grieve. "We recently announced a strategic collaboration with Entegrion Inc., a company with core expertise in human blood-related disorders.  We hope this collaboration will lead to advancing animal health by leveraging their core expertise.  In addition, this week we announced our new sublingual (or SLIT) allergy therapy product offering, adding another product which we believe will help us accelerate our revenue growth.  Heska is the veterinary industry leader in allergy testing and treatment, and this sublingual (under the tongue) therapy administration will complement our existing treatment solutions, which are predominantly subcutaneous injections, by giving pet owners an alternative delivery methodology.  We expect to announce further developments in our new product initiatives over the next few months."

    Financial ResultsFourth quarter 2011 revenue was $15.5 million as compared to $15.0 million in the fourth quarter of 2010.  In the fourth quarter of 2011, Core Companion Animal Health revenue grew approximately 6.4% to $12.8 million from $12.0 million in the prior year period and Other Vaccines, Pharmaceuticals and Products revenue decreased approximately 9.1% to $2.8 million from $3.0 million in the same timeframe.  In the third quarter of 2010, the USDA validated an improved process for a line of the company's cattle vaccines, allowing the company to ship a significant quantity of product in a category which had previously been on hold due to regulatory concerns.  Gross profit was $6.6 million, or a 42.5% gross margin, in the fourth quarter of 2011 compared with gross profit of $6.1 million, or 40.9% gross margin, in the fourth quarter of 2010.  Total operating expenses were $6.2 million, or 39.9% of sales, in the fourth quarter of 2011 compared with total operating expenses of $5.5 million, or 36.4% of sales, in the prior year period.  The Company reported operating income of $414 thousand in the fourth quarter of 2011, compared to operating income of $688 thousand in the fourth quarter of 2010.  Income before income taxes was $632 thousand in the fourth quarter of 2011, up from $576 thousand in the prior year period.  In the fourth quarter of 2011, net income was $484 thousand, or $0.09 per diluted share, compared to net income of $272 thousand, or $0.05 per diluted share, in the fourth quarter of 2010.  In the fourth quarter of 2011, the Company recorded a $172 thousand deferred tax expense compared to a $270 thousand deferred tax expense in the prior year period.

    Full year 2011 revenue was $70.1 million, an increase of 7% compared to revenue of $65.5 million in 2010.  In 2011, Core Companion Animal Health revenue grew 3.3% to $57.5 million from $55.7 million in 2010 and Other Vaccines, Pharmaceuticals and Products revenue increased 28.5% to $12.6 million from $9.8 million in 2010.  2011 Gross profit was $29.2 million, or 41.7% gross margin, compared with gross profit of $24.8 million, or 37.9% gross margin in 2010.  Total operating expenses were $25.9 million, or 37.0% of sales, in 2011 compared with total operating expenses of $24.4 million, or 37.3% of sales in 2010.  The Company reported 2011 operating income of $3.2 million up from operating income of $358 thousand in 2010.  Income before income taxes was $3.4 million in 2011, a significant increase from income before income taxes of $69 thousand in 2010.  2011 net income, inclusive of a $1.1 million deferred tax expense, was $2.1 million, or $0.40 per diluted share, compared with 2010 net income of $18 thousand, or $0.00 per diluted share.

    "Even as we invested in our organization in advance of expected growth, we have been managing expenses and effectively leveraging our infrastructure," commented Dr. Grieve.  "This is reflected in the modest year-to-date decrease in total operating expenses as a percentage of sales, to 37% of sales compared to 37.3% of sales last year, as well as in the significant increase in earnings per share, to 40 cents per diluted share for the year versus less than a penny per diluted share last year.  As a result of our continued profitability and operating efficiency, Heska has significantly strengthened its balance sheet. The Board of Directors, with a commitment to creating value for shareholders, is evaluating various alternatives with respect to our excess cash, such as a dividend or a stock buyback."

    Balance SheetAs of December 31, 2011, Heska had $6.3 million in cash and working capital of $19.6 million. Stockholders' equity increased 5.8% to $48.4 million compared to $45.8 million as of December 31, 2010.

    Investor Conference CallManagement will conduct a conference call on Friday, February 17, 2012 at 9 a.m. MST (11 a.m. EST) to discuss the fourth quarter and year-end 2011 financial results. To participate, dial (877) 941-0844 (domestic) or (480) 629-9835 (international); the conference call access number is 4511908. The conference call will also be broadcast live over the Internet at http://www.heska.com. To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software. Telephone replays of the conference call will be available for playback on Heska's home page at www.heska.com until March 2, 2012. The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international). The replay access number is 4511908.

    About HeskaHeska Corporation (NASDAQ: HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

    Forward-Looking StatementsThis announcement contains forward-looking statements regarding Heska's future financial and operating results.  These statements are based on current expectations and are subject to a number of risks and uncertainties.  Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes.  In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to Heska's ability to maintain a given level of profitability, or profitability at all; uncertainties related to Heska's commercial expansion, including the effectiveness of such efforts and ultimately Heska's ability to successfully market and sell its products in an economically sustainable manner; uncertainties related to third-party product development efforts, which Heska is significantly reliant upon; uncertainties related to the commercialization of new products, such as market acceptance; uncertainties regarding Heska's reliance on  third parties to whom Heska has granted substantial marketing rights to certain of Heska's existing products, such as Schering-Plough Animal Health Corporation which has exclusive rights to Heska's heartworm preventive in the United States; competition; risks related to Heska's reliance on third party suppliers, which is substantial; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

     

    Financial Table Follows: Consolidated Statements of Operations

    In Thousands, Except per Share Amounts

    (unaudited)

      

    Three Months Ended

    December 31,

     

    Twelve Months Ended

    December 31, 

    2010

     

    2011

     

    2010

     

    2011Revenue:

     

     Core companion animal health

    $

    11,988

     

    $

    12,754

     

    $

    55,655

     

    $

    57,481Other vaccines, pharmaceuticals and products

     

    3,027

     

     

    2,751

     

     

    9,796

     

     

    12,584Total revenue, net

     

    15,015

     

     

    15,505

     

     

    65,451

     

     

    70,065 

     

     

     

     

     

     

     

     

     

     

     Cost of revenue

     

    8,868

     

     

    8,912

     

     

    40,659

     

     

    40,878 

     

     

     

     

     

     

     

     

     

     

     Gross profit

     

    6,147

     

     

    6,593

     

     

    24,792

     

     

    29,187 

     

     

     

     

     

     

     

     

     

     

     Operating expenses:

     

     

     

     

     

     

     

     

     

     

     Selling and marketing

     

    3,122

     

     

    3,884

     

     

    14,726

     

     

    15,167Research and development

     

    297

     

     

    305

     

     

    1,597

     

     

    1,650General and administrative

     

    2,040

     

     

    1,990

     

     

    8,111

     

     

    9,121Total operating expenses

     

    5,459

     

     

    6,179

     

     

    24,434

     

     

    25,938Operating income

     

    688

     

     

    414

     

     

    358

     

     

    3,249Interest and other (income) expense, net

     

    112

     

     

    (218)

     

     

    289

     

     

    (117)Income before income taxes

     

    576

     

     

    632

     

     

    69

     

     

    3,366Income tax expense:

     

     

     

     

     

     

     

     

     

     

     Current tax expense (benefit)

     

    34

     

     

    (24)

     

     

    61

     

     

    165Deferred tax expense (benefit)

     

    270

     

     

    172

     

     

    (10)

     

     

    1,056Total income tax expense

     

    304

     

     

    148

     

     

    51

     

     

    1,221Net income

    $

    272

     

    $

    484

     

    $

    18

     

    $

    2,145 

     

     

     

     

     

     

     

     

     

     

     Basic net income per share

    $

    0.05

     

    $

    0.09

     

    $

    0.00

     

    $

    0.41Diluted net income per share

    $

    0.05

     

    $

    0.09

     

    $

    0.00

     

    $

    0.40 

     

     

     

     

     

     

     

     

     

     

     Shares used for basic net income per share

     

    5,224

     

     

    5,241

     

     

    5,220

     

     

    5,237 

     

     

     

     

     

     

     

     

     

     

     Shares used for diluted net income per share

     

    5,232

     

     

    5,340

     

     

    5,254

     

     

    5,338  

    Balance Sheet Data

    In Thousands (unaudited)

      

     

    December 31,

    2010

     

    December 31,

    2011Cash and cash equivalents

     

    $

    5,492

     

    $

    6,332

     Total current assets

     

     

    27,279

     

     

    28,891

     Property and equipment, net

     

     

    5,486

     

     

    4,869

     Total assets

     

     

    63,048

     

     

    61,894

     Line of  credit

     

     

    3,079

     

     

     Total current liabilities

     

     

    12,660

     

     

    9,289

     Stockholders' equity

     

     

    45,798

     

     

    48,439

      

     

     

     


    '/>"/>

    SOURCE Heska Corporation
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2011 Earnings Conference Call Webcast
    2. Heska to Present at the Sidoti & Company, LLC Semi-Annual New York Micro-Cap Conference
    3. Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc.
    4. Webcast Alert: Heska Announces Third Quarter 2011 Earnings Conference Call Webcast
    5. The Patent Board, IP Tracking and Analysis Firm, Ranks Heskas Science Strength in Biotechnology Industry Top 50
    6. Heska to Present at LD MICRO Invitational on September 22, 2011
    7. American Animal Hospital Association and Heska Corporation Announce New Online Continuing Education Series
    8. Heskas 2011 "Inspiration in Action" Contest Begins: Support the Veterinary Profession and Help Animals in Need
    9. Heska Retains Hayden IR to Develop Comprehensive Investor Relations Program
    10. Heska Announces 15% Revenue Growth, Fourth Consecutive Profitable Quarter, for the Second Quarter of 2011
    11. Heska to Present at SunTrust Robinson Humphreys Annual Veterinary and Dental Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
    (Date:4/28/2016)... -- Treato , the single largest ... that it has been named a Cool Vendor by ... Sciences, 2016, Stephen Davies , Michael ... life-science- oriented analytics, algorithms and smart machine technology in ... medication ingestion, and analyze unstructured information.   ...
    (Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
    Breaking Medicine Technology:
    (Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has ... go for gold in Rio. Under the care of Maximized Living doctors at ... In an unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors ...
    (Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding ... The following programs will be expanding due to high demand: Master of Business Administration ... will begin this summer. , School of Business Graduate Program Chair Dr. ...
    (Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... Two Ten Footwear Foundation, the national charitable foundation serving the footwear industry, has ... 8,000 volunteers representing more than 130 companies across 23 states during the months ...
    (Date:4/29/2016)... ... April 29, 2016 , ... ... announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for ... and mood optimization products to the store is just one more way Shamangelic ...
    (Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members ... celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care ... Cumming), offers a 70% tax credit to individuals and corporations which donate directly to ...
    Breaking Medicine News(10 mins):